Gelesis Holdings Price to Book Ratio 2021-2022 | GLS

Historical price to book ratio values for Gelesis Holdings (GLS) over the last 10 years. The current price to book ratio for Gelesis Holdings as of August 12, 2022 is 11.76.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Gelesis Holdings Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2022-08-12 1.63 11.75
2022-03-31 4.53 $0.14 32.66
2021-12-31 9.96 $-52.79 -0.19
2021-09-30 9.92 $-6.42 -1.54
2021-06-30 9.79 $0.48 20.40
2021-03-31 9.76 $0.50 19.53
2020-12-31 10.15 0.00
2020-09-30 9.83 $0.61 16.21
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.118B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.361B 9.79
GSK (GSK) United Kingdom $73.273B 8.80
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.336B 18.98
Biohaven Pharmaceutical Holding (BHVN) United States $10.564B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.449B 0.00
Arcus Biosciences (RCUS) United States $1.963B 38.31
Myovant Sciences (MYOV) United Kingdom $1.774B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.82
Zymeworks (ZYME) Canada $0.430B 0.00
Enzo Biochem (ENZ) United States $0.130B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
Ambrx Biopharma (AMAM) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00